The company's lead therapy fared well in a phase 2a trial to treat two separate conditions.
The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development
March S&P 500 futures (ESH23) are trending down -0.19% this morning after three major U.S. benchmark indices rallied on Friday, with the S&P 500 and Dow snapping a three-session losing streak and the Nasdaq...
These drugmakers have bucked the overall market's downward trend this year and expectations are still high.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused...
Here's why we like Novavax, Orthopediatrics, and Pliant Therapeutics.
SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809, its oral,...
Wall Street thinks this red-hot biotech stock has a lot more room to run.